Scientific Advisory Board

Thomas Helleday, PhD, Professor Karolinska Insitutet, Sweden. Chairman of the SAB.

Giorgio Massimini, MD, PhD. Dr. Massimini has dedicated his career to oncology clinical development. He was responsible for clinical trials of Roferon-A, Interleukin 2, and G-CSF, leading to international marketing approvals for Roferon-A. He was recently retired from his position as Vice President, Head Medical Officer at Merck Biopharma.

Andrea Wahner Hendriksson, MD, PhD, Associate Professor of Oncology, Mayo clinical, Chester Minnesota. Dr. Wahner is a clinical-investigator and part of the Mayo Clinic Phase 1 group and the NIH-funded Mayo Clinic Ovarian Cancer Specialized Program of research Excellence (SPORE) grant.

Sarah Danson, MD, PhD, deputy Director, Weston Park cancer Centre. Dr Danson is a medical oncologist, and chair of the Adult ECMC Network UK. She is Weston Park Cancer Centre Deputy Director and NHR National Specialty Lead for Cancer Early clinical Phase.

Mikael von Euler, MD, PHD, EFPM. Dr. von Euler is an oncologist with > 30 years of experience in the pharmaceutical industry, e.g. as Cluster Head for the Her2 area (Herceptin, pertuzumab, T-DM1) at Roche/Genentech, Vice President of Oncology Europe at GlaxoSmithKline and Global Production Director of Arimidex/Nolvadex at AstraZeneca.